Previewing Revolutionizing Atopic Dermatitis 2025, with Mona Shahriari, MD

As dermatology rapidly advances, the Revolutionizing Atopic Dermatitis (RAD) Annual Meeting continues to serve as a key platform for learning, collaboration, and progress in patient treatment.

Interest in atopic dermatitis has surged, alongside major therapeutic breakthroughs. With more treatment options than ever before, translating that knowledge into everyday clinical practice has made education for providers increasingly essential.

"Given how the [atopic dermatitis] landscape has changed so dramatically over the last several years," explained Mona Shahriari, MD, "I think this is a nice time for us to be able to talk about not only the various treatments that we have, but also how do we optimize treatment for patients, by taking those treatments and appropriately giving them to the patients that are in need, and defining what is adequate control, what is that bar for efficacy that we should be reaching for?"

At RAD 2024, attendees were introduced to important data from the LEVEL UP initiative, the Measure Up program, and the DELTA studies. In addition to covering clinical trials and evolving guidelines, the RAD meeting emphasizes other critical aspects of care, including treatment approaches for skin of color, managing comorbidities, and more.

In this interview, Shahriari—who is set to lead a session at the upcoming meeting in Nashville, TN, from June 06–07, 2025—explains why RAD has become a standout event for clinicians treating atopic dermatitis. He highlights what sets the meeting apart: sessions, speakers, and conversations that zero in on real-world issues, practical care, and patient-centered strategies.

Reference:

Campbell P. MJH Life Sciences Celebrates Acquisition of Revolutionizing Atopic Dermatitis (RAD) Annual Meeting. HCP Live. Published November 11, 2024. Accessed April 9, 2025. https://www.hcplive.com/view/mjh-life-sciences-celebrates-acquisition-of-revolutionizing-atopic-dermatitis-rad-annual-meeting.